H. pylori Testing in Canada vs the US: Which Classification Route Applies?

Quick facts

• Helicobacter pylori testing is an in vitro diagnostic question, not a general laboratory question. The class depends on what the test detects and where it is run.
• United States: the urea breath test for H. pylori sits in the FDA classification database under product code OZA at Class III, with premarket approval submissions such as P100025 recorded against that code. A separate urea test code, MSQ, is recorded at Class I.
• United States: the product code and the premarket approval are the reliable references for this test, because the regulation number shown against the OZA entry in the classification database does not match the section title carried at that number in the current CFR.
• Canada: the Medical Devices Regulations, SOR/98-282 classify an in vitro diagnostic device by rule in Part 2 of Schedule 1. A test used for patient management is Class II under Rule 3, unless the patient is being managed for a life-threatening disease or an erroneous result would lead to an imminent life-threatening situation.
• Canada: where the same test is run outside a laboratory, at home or at the point of care, it is a near patient IVDD and is Class III under Rule 6.
• The difference is the site, not the chemistry. An American urea breath test and a Canadian one may be the same kit; the Canadian class moves with the site of testing.
• Canadian regulation text used here is current to 2026-09-21 and last amended 2026-06-17, as stated on the official consolidation.

H. pylori testing is a useful case because it spans the whole diagnostic range in one organism: a breath test that is an approved high-risk device in one country, a laboratory immunoassay, and a point-of-care kit sold for use in a consulting room. The two countries reach different answers, and the Canadian answer changes with the site of testing. This article sets out the American product-code route, the Canadian rule route, what each test method detects, and what a laboratory or clinic should keep on file.

What does H. pylori testing actually detect?

Four method families, and they do not measure the same thing.

• The urea breath test. The patient swallows urea labelled with carbon-13, and H. pylori urease splits it if the organism is present. The labelled carbon dioxide is then measured in exhaled breath. The test detects active urease activity, which is a marker of current infection.
• The stool antigen test. An immunoassay against an H. pylori antigen in stool. It detects the presence of the organism rather than its activity.
• The serology test. An antibody assay on serum or plasma. It detects exposure, and antibody can persist after the organism has cleared, so a positive result does not by itself show current infection.
• The biopsy-based test. Rapid urease testing, histology or culture on a specimen taken at endoscopy. This is the route that allows culture and susceptibility testing.

That is the clinical spine of the article, and it is also the regulatory spine. A test that detects a current infection and guides treatment is used for patient management. A test that detects exposure is used differently. The classification rules in both countries turn on the intended use the maker writes.

Method	What it detects	When the result is read relative to therapy
Urea breath test	Urease activity of a current infection	Before treatment, and after treatment to confirm clearance
Stool antigen test	H. pylori antigen	Before treatment, and after treatment to confirm clearance
Serology	Antibody indicating exposure	Not used to confirm clearance, because antibody persists
Rapid urease or histology on biopsy	Organism at the biopsy site	At endoscopy; sampling can miss a patchy infection

How does the same test differ between Canada and the United States?

Item	Canada	United States
Classification instrument	Part 2 of Schedule 1 to the Medical Devices Regulations	Device classification database and the CFR
Urea breath test run in a laboratory	Rule 3, Class II as an IVDD for patient management	Product code OZA, Class III, with premarket approval
Urea breath test run outside a laboratory	Rule 6, Class III as a near patient IVDD	Same product code; the site does not change the class
Class moves up where	Rule 3(a) or 3(b): life-threatening disease management, or an erroneous result that would prompt a decision creating an imminent life-threatening situation	Different intended uses point to different product codes
Regulatory floor	Rule 8: if rules 1 to 7 do not apply, all other IVDDs are Class I	Class assignment is by product code
Practical consequence	The same kit can be Class II or Class III depending on where it is used	The class is fixed by the product code the maker holds

The table's fourth row is the point that matters commercially. In Canada the class of a near patient IVDD does not depend on how accurate the test is or how benign the condition is. Rule 6 reads: a near patient IVDD is classified as Class III. The definition of the term is equally flat: a near patient in vitro diagnostic device means an in vitro diagnostic device that is intended for use outside a laboratory, for testing at home or at the point of care, such as a pharmacy, a health care professional's office or the bedside.

There is one exception, and it is a table. Rule 9 states that despite rules 1 to 8, an IVDD set out in column 1 of the table to that rule is classified as the class in column 2. The table lists two near patient cases that fall back to Class II: a device for the detection of pregnancy or for fertility testing, and a device for determining cholesterol level. It also lists two classes of microbiological media at Class I.

A near patient breath test for H. pylori is not in that table. It stays where Rule 6 puts it.

Why does the site of testing decide the Canadian class?

Because Canada writes the site into the classification rule and the United States does not.

An IVDD used for patient management is Class II under Rule 3 unless one of two conditions is met. Condition (a) is that it is intended to be used for the management of patients suffering from a life-threatening disease. Condition (b) is that there is a risk that an erroneous result will lead to a patient management decision resulting in an imminent life-threatening situation for the patient.

A laboratory run H. pylori test for the diagnosis of infection generally sits in Class II under that rule, because the infection is treated and followed up rather than being an immediately life-threatening condition in most patients. The rule is written around the patient's situation, not the organism.

Move the same test to a consulting room or a pharmacy and Rule 6 applies instead, and the answer becomes Class III. Nothing about the chemistry changed. What changed is that the result is delivered without a laboratory between the test and the decision.

That is a real operational difference for a Canadian clinic that is considering a point-of-care kit. The class of the device the clinic wants to use is higher than the class of the laboratory version of the same test, and the licensing and documentation burden follows the class.

What should a laboratory record for an H. pylori assay?

Six items, and three of them are about the platform rather than the kit.

• The method and the intended use. Breath, stool antigen, serology or biopsy-based, with the maker's stated purpose, because the rule that applies in Canada follows the stated purpose.
• The site of testing. Laboratory or point of care, because that single fact moves the Canadian class between Rule 3 and Rule 6.
• The specimen path. Collection, transport and storage conditions, since a stool or breath specimen has a defined stability window and the record should name it.
• The pre-treatment and post-treatment status of the patient. A test used to confirm clearance is being used at a different point in the care pathway from one used for initial diagnosis.
• The platform and its calibration. The instrument, the lot of reagents and the calibration record for the run.
• The kit's regulatory status. In Canada, the class and licence position; in the United States, the product code and the premarket approval or clearance that covers the device as marketed.

Which consumables does a laboratory restock alongside its assay platform?

A laboratory restocks specimen containers, transport packaging, pipettes and bench consumables on the same cycle as its analysers. For laboratories buying at case level, the wholesale ordering page sets out account and case terms, and the B2B wholesale collection lists the lines held for institutional buyers. The specimen cups cover the collection step, the 95 kPa specimen transport bags cover the transport step, and a laboratory that wants the monitoring and consumable lines together can start with the sterilization monitoring collection or the biological indicator 5-pack trial.

Sources

1. Medical Devices Regulations, SOR/98-282, full text with Schedule 1 Parts 1 and 2
2. openFDA device classification API
3. FDA device classification database
4. FDA premarket approval database
5. 21 CFR 866.3110, as published in the current CFR
6. 21 CFR 862.2050, general purpose laboratory equipment
7. 21 CFR 864.3600, microscopes and accessories
8. ISO 15189:2022, medical laboratories, requirements for quality and competence
9. ISO/IEC 17025:2017, competence of testing and calibration laboratories
10. ISO 11607-1:2019, packaging for terminally sterilized medical devices
11. CLSI standards and products
12. Public Health Ontario, laboratory services test information index
13. Public Health Ontario, infectious diseases
14. Ontario Laboratory Medicine Act, R.S.O. 1990, c. L.1
15. College of Medical Laboratory Technologists of Ontario
16. World Health Organization, laboratory quality management system
17. Canadian Centre for Occupational Health and Safety, OSH answers
18. US OSHA bloodborne pathogens standard, 1910.1030
19. Health Canada, medical devices
20. ISO 11607-1:2019, packaging for terminally sterilized medical devices

Related reading

• At-Home COVID and Flu Test Kits in Canada vs the US: Which Rules Apply
• Blood Culture Bottles in Canada vs the US: Which Rules Apply
• 24-Hour Urine Collection in Canada vs the US: Which Container Rules Apply

CliniEco Medical supplies eye care, laboratory and clinic consumables of the kind described in this article. MDEL #35334. This article is written for laboratory, clinic and procurement professionals and is not clinical guidance; the choice of test, the timing of a test relative to treatment and the interpretation of a result belong to the treating professional and to the requirements that apply to the laboratory.

Frequently Asked Questions

What class is an H. pylori urea breath test in the United States?

The FDA classification database records the urea breath test under product code OZA at Class III, and premarket approval submissions are recorded against that product code. A separate urea test code, MSQ, is recorded at Class I, so the product code the maker holds is the thing to check.

Why is the regulation number for that product code not usable here?

Because the regulation number shown against the OZA entry in the classification database does not match the section title carried at that number in the current CFR. For this test the product code, the device class and the premarket approval record are the reliable references, and they are the fields the database returns directly.

What class is an H. pylori test in Canada?

It depends on the site. An in vitro diagnostic device used for patient management is Class II under Rule 3 of Part 2 of Schedule 1, unless the patient is being managed for a life-threatening disease or an erroneous result would lead to an imminent life-threatening situation. A near patient IVDD, used outside a laboratory at home or at the point of care, is Class III under Rule 6.

Does the Rule 9 table reduce the class of a near patient H. pylori test?

No. The table in Rule 9 lists near patient devices for pregnancy or fertility testing and for determining cholesterol level at Class II, and microbiological media at Class I. A near patient breath test for H. pylori is not in that table, so Rule 6 continues to apply.

Does serology follow the same route as a breath test?

Not necessarily. The rules turn on intended use, and a serology assay that detects exposure is used differently from a test that detects current infection and is used to confirm clearance. The maker's stated purpose is what the classification follows, which is why the intended use has to be read before the class is assumed.

What should a clinic or laboratory keep on file for an H. pylori assay?

The method and the maker's intended use, the site of testing, the specimen path and stability window, the point in the care pathway at which the test is used, the platform and reagent lot with the calibration record, and the device's regulatory status in the country where it is used.